This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEB9606Q_M.jpg
Orbimed Advisors’s holding in LogicBio Therapeutics, Inc. increased to about 296 thousand shares with the purchase.
Orbimed Advisors first bought LogicBio Therapeutics, Inc. stock in the fourth quarter of 2018. Orbimed Advisors also owns Bristol-Myers Squibb Co (NYSE:BMY), Merck (MRK), Mirati Therapeutics Inc (NASDAQ:MRTX) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX). LogicBio Therapeutics, Inc. is its number fifty three position by number of shares and market value among biotechnology & life sciences stocks.
Other investors who also added to their LogicBio Therapeutics, Inc. shares include California State Teachers Retirement System. Contrary to Orbimed Advisors, Victory Capital Management sold all their LOGC shares.
Orbimed Advisors has also recently reduced their share in Alector, Inc. (NASDAQ:ALEC). The total value of the shares sold is estimated at around $105 million.
In addition, Orbimed Advisors added to their share in Alpine Immune Sciences, Inc. (NASDAQ:ALPN), Adicet Bio, Inc. (ACET) and TELA Bio, Inc. (NASDAQ:TELA). The total value of the shares bought is estimated at around $79 million.
Orbimed Advisors also reduced their share in ESSA Pharma Inc . (NASDAQ:EPIX) and 89bio, Inc. (NASDAQ:ETNB). The total value of the shares sold is estimated at around $54 million.
Additionally, Orbimed Advisors established new holdings in Fusion Pharmaceuticals Inc. (FUSN). The total value of the shares bought is estimated at around $52 million.
